Patent classifications
C07D473/06
SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.
USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.
PURINE COMPOUNDS FOR TREATING DISORDERS
Substituted purine compounds of formula (I)-(III) and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's 5 and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.
##STR00001##
PURINE COMPOUNDS FOR TREATING DISORDERS
Substituted purine compounds of formula (I)-(III) and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's 5 and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.
##STR00001##
8-SUBSTITUTED DIARYL XANTHINES AS DUAL A2A-A2B ANTAGONISTS
The present invention relates to 8-substituted diaryl xanthines and pharmaceutical compositions thereof that are antagonists of A.sub.2A and/or A.sub.2B adenosine receptors (ARs).
8-SUBSTITUTED DIARYL XANTHINES AS DUAL A2A-A2B ANTAGONISTS
The present invention relates to 8-substituted diaryl xanthines and pharmaceutical compositions thereof that are antagonists of A.sub.2A and/or A.sub.2B adenosine receptors (ARs).
Small molecules for the treatment of primary cancer and cancer metastasis
Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.
Small molecules for the treatment of primary cancer and cancer metastasis
Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.